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1. Introduction 
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a remarkably 
successful pathogen that has latently infected a third of the world population (Zhang et al., 
2006). Infection occurs via aerosol, and inhalation of a few droplets containing M. 
tuberculosis bacilli is enough for lung infection (Hassan et al., 2006). After infection, M. 
tuberculosis pathogenesis occurs in two stages. The first is an asymptomatic state that can 
persist for many years in the host, called latent TB. The second stage requires only a 
weakened immune response to become activated (Zhang, 2004), then the bacteria begins 
replicating and causing characteristic symptoms such as cough, chest pain, fatigue and 
unexplained weight loss. If left untreated, the disease eventually culminates in death. The 
emergence of Human Immunodeficiency Virus (HIV) and the resultant Acquired Immune 
Deficiency Syndrome (AIDS) pandemic underlined the importance of reactivation of the 
disease and its potentially catastrophic outcome since over 50% of deaths among HIV-
infected patients results from co-infection with M. tuberculosis with the two pathogens 
inducing each other’s replication, thus accelerating the collapse of the immune system (Cole 
& Alzari, 2007). 
While it is impossible to determine the exact number of cases, the latest World Health 
Organization (WHO) survey estimates that close to 2 million deaths occur every year, that 
there are approximately 8 million new cases annually, and that every third individual on the 
planet has been exposed to or infected by M. tuberculosis (Dye, 2006; Cole & Alzari, 2007). 
Although TB can be treated and even cured with chemotherapy, treatment is exceedingly 
lengthy and takes 6-9 months (Blumberg, et al., 2003). In addition to significant toxicity, 
lengthy therapy also causes poor patient compliance, which is a frequent cause for selection 
of drug resistant and often deadly multidrug resistant TB (MDR-TB) bacteria (Zang et al., 
2006). 
Currently, TB chemotherapy is made up of a cocktail of first-line drugs, isoniazid (INH), 
Rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB), which are given for six 
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months (Blumberg et al., 2006). If this treatment fails as a result of bacterial drug resistance 
or intolerance to one or more drugs, second-line drugs are used, such as para-aminosalicilate 
(PAS), kanamycin, fluoroquinolones, capreomycin, ethionamide and cycloserine. These are 
generally less effective or more toxic with serious side effects (Blumberg et al., 2006). This 
second-line treatment can also result ineffective since MDR-strains that exhibit resistance to 
these second-line drugs are currently on the rise (Zhang & Amzel, 2002) 
Treatment is also made quite difficult by the presence of metabolically silent, persistent or 
dormant bacteria within host lesions. These are not susceptible to the anti-mycobacterial 
drugs that usually kill growing but not persistent bacteria (Zhang, 2004). While there are 
many reasons for drug resistance, including prescription of inadequate regimens, an 
uncertain drug supply, and ineffective drugs, duration of lengthy treatments is one of the 
major contributors because some TB patients prematurely stop their therapy after an initial, 
rapid heath improvement, thereby favoring the emergence of drug-resistant strains (Cole & 
Alzari, 2007) 
2. Anti-TB drug targets 
Despite the relative efficacy of current treatment, the various antibiotics that constitute first- 
and second-line drugs for TB therapy target only a small number of core metabolic 
processes such as Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) synthesis, cell 
wall synthesis, and energy metabolism pathways (Zhang, 2005). New classes of drugs with 
additional drug targets that are difficult to overcome by mutation are urgently needed 
(Hansan et al., 2006). Desirable new targets should be involved in vital aspects of bacterial 
growth, metabolism and viability whose inactivation would lead to bacterial death or an 
inability to persist, thus therapy could be shortened and drug resistant strains could be 
eliminated or drastically reduced (Mdluli & Spigelman, 2006; Duncan, 2004). Moreover, 
targets involved in the pathogenesis of the disease process should also be considered for 
drug development (Zhang et al., 2006; Palomino et al., 2009). 
The discovery of the complete genome sequence of TB bacteria helped to identify several 
important drug targets (Cole et al., 1998). Various groups have used this genomic 
information to identify and validate targets as the basis for development of new Anti-TB 
agents. Besides, mycobacterial genetic tools, such as transposon mutagenesis, gene 
knockout, and gene transfer, greatly facilitate target identification.   
2.1 Cell wall biosynthesis related targets 
Cell wall biosynthesis is a particularly good source of molecular targets because the 
biosynthetic enzymes do not have homologues in the mammalian system (Mdluli & 
Spigelman, 2006).  The cell wall of M. tuberculosis is very important for its survival within 
constrained conditions such as those inside of human macrophages. The biosynthesis of the 
cell wall components involves many important stages and different enzymes that are absent 
in mammals and could be attractive drug targets (Khasnobis et al., 2002; Brennan & Crick, 
2007; Sarkar & Suresh, 2011). Recently, the 2C-methyl-D-erytrol 4-fosphate (MEP) pathway 
was found (Eoh et al., 2009) as a potential drug target since the end product of the pathway 
leads to the formation of isoprenoids, which are responsible for the synthesis of several cell 
wall components (Mahapatra et al., 2005; Anderson et al., 1972). 
Peptidoglycan biosynthesis is another source of potential drug targets. For instance, alanine 
racemase and D-Ala-D-Ala-ligase catalyze the first and second committed steps in bacterial 
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peptidoglycan biosynthesis, and since these steps are essential for important polymers, they 
are good drug targets. Both alanine racemase and D-Ala-D-Ala ligase are inhibited by D-
cycloserine, a second line anti-TB drug (Strych et al., 2001; Feng & Barletta, 2003).  
Another good drug target is the pyridoxal 5’-phosphate containing enzyme Alr that 
catalyzes the racemization of L-Alanine into D-Alanine, a major component in the 
biosynthesis of peptidoglycan (LeMagueres et al., 2005). 
Arabinogalactan biosynthesis, a novel arabionofuranosyl transferase that catalyzes the 
addition of the first key arabinofuranosyl redisude of the galactan core, is not sensitive to 
EMB, but is essential for viability (Sassetti et al., 2003). The ribosyltransferase that catalyzes 
the first committed step in the synthesis of decaprenyl-phosphoryl-D-arabinose, the lipid 
donor of mycobacterial d-arabinofuranosyl residues, has also recently been characterized 
and shown essential for growth (Huang et al., 2005) 
2.2 Mycolic acid biosynthesis related targets 
Within the mycobacteria lipid metabolism, mycolic acids are essential structural components 
of the mycobacterial cell wall (Brennan, 2003). The early stage of fatty acid biosynthesis, which 
generates the precursors of mycolic acids, is a rich source of antibacterial targets (Heath et al., 
2001). It is also the site of action of INH and ethionamide (Quemard et al., 1995; Larsen et al., 
2002).  M. tuberculosis has both types of fatty acids synthase (FAS) systems found in nature, 
FAS-I and FAS-II. FAS I is the system responsible for de novo synthesis of C16-C26 fatty acids 
and the FAS II system extends these fatty acids up to C56 chains to make precursors of mycolic 
acids, which are essential for growth.  
Since enoil-ACP reductase (InhA) is the target of INH, it is reasonable to assume that all 
steps in the FAS-II pathway will be essential for the viability of M. tuberculosis. Many of the 
individual enzymes of the FAS-II system have been expressed, purified and characterized 
(Kremer et al., 2001; Choi et al., 2000; Scardale et al 2001; Benerjee et al 1998; Marrakchi et 
al.,2002; Marrakchi et al., 2000; Slayden & Barry, 2002). 
2.3 Energy production related targets 
Isocitrate lyase (ICL) is an important enzyme in this category and also an important drug 
target. ICL is involved in energy production via the metabolism of acetyl-CoA and 
propionial CoA of the glyoxilate pathway. Inactivation of the icl gene leads to attenuation of 
both persistent and virulent strains of M. tuberculosis. However, M. tuberculosis has a salvage 
pathway, so a suitable anti-TB drug for this target must address both the main and salvage 
pathways (McKinney et al., 2000; Savi et al., 2008)  
2.4 Amino acid biosynthesis related drug targets 
Amino acid biosynthesis is another important target for developing anti-TB drugs. The 
shikimate pathway is very important and is involved in the synthesis of aromatic amino 
acids in algae, fungi, bacteria, and higher plants; however, it is absent in the mammalian 
system (Sarkar & Suresh, 2011). The final product of the shikimate pathway, chorismate, is a 
key biosynthetic intermediate involved in generating aromatic amino acids and other 
metabolites. The entire pathway is essential in M. tuberculosis (Parish & Stoker 2002). This 
feature makes the pathway an attractive target for developing anti-TB drugs with minimum 
cross reactivity (Ducati et al., 2007). Other enzymes of this pathway are also likely to be 
essential, and shikimate dehydrogenase (Magalhaes et al., 2002), and 5-
enolpyruvylshikimate 3-phosphate synthase (Oliverira et al., 2001) have been characterized 
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in detail. The biosynthesis of non-aromatic amino acids is also emerging as a potential drug 
target. The impact of amino acids such as lysine (Pavelka & Jacobs, 1999), proline, 
tryptophan and leucine (Smith et al., 2001) is evident from the fact that knocked out M. 
tuberculosis strains of the genes required for amino acid biosynthesis showed less virulence 
(Pavelka et al., 2003; Smith et al., 2001). Another attractive target of the lysine biosynthesis 
pathway is the enzyme dihydrodipicolinate reductase, for which potent inhibitors have 
been identified (Paiva et al., 2001).  
2.5 Cofactor-related drug targets 
Several cofactor biosynthetic pathways and pathways requiring some cofactors are good 
candidates for identification of new drug targets. Folate derivatives are cofactors utilized in 
the biosynthesis of essential molecules including purines, pyrimidines, and amino acids. 
While bacteria synthesize folate de novo, mammals must assimilate preformed folate 
derivatives through an active transport system (Mdluli & Spigelman, 2006). Dihydrofolate 
reductase, which catalyses the reduction of dihydrofolate to tetrahydrofolate, a key enzyme 
in folate utilization whose inhibition may affect the growth of M. tuberculosis (Gerum et al., 
2002), and dehydropteroate synthase are validated targets of the widely used antibacterial 
sulfonamide, trimethoprim (Huovinen et al., 1995).  
Two enzymes involved in the de novo biosynthesis of NAD that affects the NADH/NAD+ 
ratio upon which M. tuberculosis is dependent, have been studied as possible drug targets 
(Bellinzoni et al., 2002). Genomic analysis studies have suggested that the riboflavin 
biosynthesis pathway is essential in M. tuberculosis (Morgunova et al., 2005) and  the 
lumazine synthase pathway has been validated as a target for anti-TB drug discovery. 
2.6 DNA metabolism 
Differences in mammalian and mycobacterial thymidin monophosphate kinase have been 
studied and exploited in an attempt to find selective inhibitors for this drug target (Haouz et 
al., 2003; Vanheusden et al., 2002). Other targets are ribonucleotide reductases that catalyze 
the first committed step in DNA synthesis and have differences with  corresponding 
mammalian enzymes (Yang et al., 1994; Yang et al., 1997); DNA ligases, that play an 
important role in the replication and repair of DNA, are classified as NAD+ or ATP 
dependent. NAD+ dependent ligases are only found in some viruses and eubacteria (Mdluli 
& Spigelman, 2006). LigA is essential for growth of M. tuberculosis (Gong et al., 2004) and 
inhibitors that distinguish between the two types of ligases and have anti-TB activity have 
been identified (Srivastava et al., 2005). DNA gyrase has also been validated as a target for 
M. tuberculosis, since this is the only type II topoisomerase that it possesses (Cole et al., 1998). 
Its inhibition by fluoroquinolones results in highly mycobactericidal activity. 
2.7 Menaquinone biosynthesis 
It appears that menaquinone is the only quinone in M. tuberculosis, so its biosynthesis is 
essential for growth. The menaquinone pathway is not present in humans, and bacterial 
homologues of MenA-E and MenH have been described in M. tuberculosis, so this pathway 
is another promising drug target (Meganathan, 2001). 
2.8 Other potential drug targets in M. tuberculosis 
The tubercle bacillus produces no less than 20 cythochrome p450 enzymes, some of which 
appear to play essential roles (Cole & Alzari, 2007). Antifungal azole drugs target these 
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enzymes and the cytochrome p450 homologues in the bacteria. Drugs like miconazole and 
clotrimazole are active against M. tuberculosis (McLean et al., 2007; Ahmad et al., 2006; Sun et 
al., 1999 TD). Subsequent crystallization studies of the M. tuberculosis cytochrome p450 
enzyme system evoked studies to evaluate new drugs (Leys et al., 2003). 
Peptide deformylase inhibitors may be effective against M. tuberculosis since peptide 
deformylase catalyzes the hydrolytic removal of the B-terminal formyl group from nascent 
proteins. It is a metalloprotease essential for maturation of nascent polypeptides in bacteria 
but not essential for humans, making it an attractive target for antibacterial drug 
development (Teo et al., 2006); however, it has little effect on slow growing TB bacteria 
(Khasnobis et al., 2002). 
Another important set of emerging drug targets are the components of the siderophore 
biosynthesis of M. tuberculosis (Monfeli et al., 2007). Upon infection, as a part of the defense 
mechanism, the host has several mechanisms to withdraw or control the free extracellular, 
as well as intracellular, iron concentration (Weinberga & Miklossy, 2008; Ferreras et al., 
2005). Mycobacteria have an unusual reliance on serine/threonine protein kinases as the 
main component of signal transduction pathways (Av-Gay & Everett, 2000), and there is 
considerable activity around this transduction system since some of these enzymes are 
essential for growth (Fernandez et al., 2006). M. tuberculosis synthesizes mycothiol in a 
multistep process involving four enzymatic reactions for protection against the damaging 
effects of reactive oxygen species. This pathway is absent in humans, and it has been shown 
to be essential to M. tuberculosis (Sareen et al., 2003). 
3. Rational drug design 
One of the design strategies for new anti-TB compounds is based on the development of 
analogs of first-line and/or second line drugs. In this section we review the strategies 
employed and analyze structure-activity relationships (SAR), which have led to the 
development of new anti-TB agents. In addition, we review new pharmacophore groups. One 
problem that must be considered in the design of anti-TB compounds is that there is a 
subpopulation of bacteria in a persistent non-replicating state. This is considered a major 
contributing factor to long drug treatments for TB. For this reason, it is important to determine 
if compounds have potential activity against these bacteria at the onset of design. We should 
also consider the physicochemical properties that directly affect the pharmacokinetics and 
pharmacodynamics of drugs. An example of this is the influence of stereoisomers on biological 
activity, because individual enantiomers have significant differences in activity, although 
sometimes the activity of some enantiomers cannot be explained. 
3.1 Isoniazid derivatives 
One of the strategies frequently used in medicinal chemistry to develop new drugs is 
“hybridization”, a method that has been proposed particularly for new anti-TB drugs. An 
example is the design of molecules based on INH or PZA, incorporating NR1R2 groups 
derived from a second anti-TB molecule or possibly other nucleophilic groups to provide 
anti-TB activity. With special interest compounds 1 and 2 (figure 1) were obtained. These 
could be considered prodrugs because they contain two conventional drugs that are bound 
by a CH fragment. Although the results of activity are very similar to those presented by 
INH and PZA, the hydrolysis of new compounds ensures prolonged release of the active 
drugs (Imramovsky et al., 2007). 
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A variety of compounds derived from INH that include mostly a hydrazine fragment have 
been determined. Following this strategy and considering the inclusion of an oxadiazole 
moiety, Navarrete et al, developed new agents with high anti-TB activity (3, figure 1). Due 
to the substitution in 5-position on the oxadiazole ring, the compounds obtained showed 
high lipophilicity, hypothesizing that this lipophilicity could facilitate passage of these 
compounds through the M. tuberculosis bacterial membrane (Navarrete-Vazquez et al., 
2007). Also, structural modification of the hydrazide moiety on INH (4, figure 1) provided 
lipophilic adaptations of the drug that blocked the N-acetylation process, obtained high 
levels of in vitro activity against M. tuberculosis and macrophages infected, as well as low 
toxicity (Hearn et al., 2009). 
Another strategy in drug design is the formation of molecules that mimic the natural 
substrate of an enzyme. Delaine et al designed a new series of bi-substrate-type inhibitors 
based on a covalent association between molecules mimicking the INH substrate and the 
NAD cofactor that could provide compounds with a high affinity and selectivity for the 
INH catalytic site (5 and 6, figure 1). In these compounds, the authors determined that 
incorporating a lipophilic component into the nicotinamide hemiamidal framework 
provides more active derivatives (Delaine et al., 2010). 
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Fig. 1. Structure of compounds derivatives of anti-TB first line drugs. 
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3.2 Ethambutol derivatives 
Amino alcohols that include EMB, which is used for pharmacological TB treatment, are an 
important class of compounds with various applications. This compound has been widely 
studied determining that the 1,2-ethylenediamine moiety is the EMB pharmacophore, 
possibility due to chelate bond formation with divalent metal ions such as copper. Based on 
EMB, a second-generation agent has been developed, a compound called SQ109 (7, figure 2), 
which is being tested in clinical trials. It is a drug that exhibits potent activity against M. 
tuberculosis strains, including multidrug resistant strains in vitro and in vivo. Unfortunately, 
SQ109 has poor bioavailability of only 12% and 3.8% in rats and dogs, respectively. Studies 
indicate that this compound undergoes oxidation, epoxidation and N-dealkylation, which 
cause its low bioavailability; therefore strategies have been designed to improve its 
bioavailability minimizing this first-pass effect. Prodrugs based on carbamate groups are a 
good option for reducing this effect. Considering this Meng and colleagues developed a new 
series of analogues based on carbamate prodrugs of SQ109 (8, figure 2) that provide good 
chemical stability as substrates of plasma esterase. The results of bioavailability of these 
compounds show a five-fold increase of the SQ109 reference compound (Meng et al., 2009). 
Alternatively, Zhang has carried out the synthesis of new analogues of S2824 (9, figure 2), a 
second-generation compound derived from EMB. The results show that new analogues with 
a homopiperazine ring (10, figure 2) have high in vitro activity against both sensitive and 
drug-resistant M. tuberculosis strains (Zhang et al., 2009).   
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Fig. 2. Structure of SQ109 and analogs. 
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In the design of new 1,2-diamine derivatives (11, figure 3) compounds with 35 times more 
activity than EMB have been synthesized. Interestingly, studies show that they do not have 
the same target as EMB. An SAR analysis has determined that the presence of an β-hydroxy 
group on the amine increases anti-TB activity; however, the distance between oxygen and 
nitrogen atoms in EMB are the same as between both atoms in the hydroxyethylamine 
suggesting a good relationship between both structures (12, figure 3). In a new series of EMB 
analogs obtained by Cunico et al, it was determined that the sulfonamide moiety reduces 
activity against M. tuberculosis, and that the amino alcohol moiety on 
hidroxyethylsulfonamide is crucial for anti-TB activity, where the presence of a carbamate 
moiety leads to a loss of activity. Consistent with this, it has been reported that if 
compounds lose the basicity of the amino group (12, figure 3), this results in a loss of activity 
(Cunico et al., 2011). Finally, EMB has served as a proposal for tripartite hybridization 
(chloroquine, isoxyl and ethambutol) for the development of new anti-TB agents (13, figure 
3), which exhibit high activity against M. tuberculosis (Nava-Zuazo et al., 2010). 
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Fig. 3. Ethambutol analogs as anti-TB agents. 
3.3 Salicylanilides derivatives 
salicylanilides (SAL) derivatives have been of great interest in medicinal chemistry, 
although their mechanism of action still unknown. It is postulated that they serve as 
epidermal growth factor receptor protein kinase (EGFR PTK) inhibitors. Such compounds 
have generally been designed to compete with adenosine triphosphate (ATP) in binding 
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with the catalytic domain of tyrosine kinase. Recent studies specify that selective inhibitors 
of interleukin-12p40 production also have a specific role in the initiation, expansion, and 
control of the cellular response to TB. Following the development of SAL derivatives, 
Imramovskỳ´s group obtained a series of compounds (14, figure 4) with activity similar to 
INH. Through a SAR study, they established that positions R1 and R2 showed Cl and Br 
atoms that are necessary for high activity against TB and that the benzyl and isopropyl 
substituent at R3 increases activity (Imramovskỳ et al., 2009). 
In addition, in various SAL derivatives that have been developed it has been shown that 
electron withdrawing groups on the salicyloyl ring and hydrophobic groups on the anilide 
ring, as well as the 2-hydroxy group, are essential for optimal antimicrobial effect. Halogen-
substituted SAL in both parties maintains the requirements and forms of more active 
derivatives that show anti-TB activity. However, its unsuitable physical properties led to the 
generation of prodrugs of SAL derivatives with better bioavailability, and due to a high 
degree of lipophilicity, more efficient transport through M. tuberculosis cell membranes. 
Considering this, Imramovskỳ and colleagues obtained compounds (15, figure 4) with 
interesting activity against M. tuberculosis. They showed a level of inhibition of 89%-99%and 
an MIC of 3.13 µg/mL. Although, they demonstrated that lipophilicity is a secondary 
parameter in anti-TB activity, they also demonstrated that in these compounds the 
stereoisomer effect is important for anti-TB activity; however, in this case the difference is 
not determined for individual R/S isomers (Imramovskỳ et al., 2009). 
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Fig. 4. General structure of salicylanilides derivatives with anti-TB activity. 
Using the hybridization strategy, Ferriz et al obtained a new series of derivatives with SAL 
and carbamate groups, which have been used as antibacterial and antiviral agents. Thus the 
hybridization of two moieties could produce a new series with changes in their 
pharmacokinetic and pharmacodynamic properties. Ferriz et al postulated that carbamate 
could be protecting these molecules against first-pass metabolism, increasing their activity 
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profile. The series obtained show that Cl atoms at 3 and 4-position on the aniline ring 
increase M. tuberculosis biological activity. Interestingly, the presence of an alkyl chain also 
increases the biological activity of these compounds, which suggests the importance of 
carbamate group (16, figure 4). Although these kinds of compounds are consistent with the 
Lipinski rules, it is speculated that due to their high lipophilicity, these molecules have high 
permeability, making their release more effective (Ferriz et al., 2009).  
Another strategy using SAL derivatives has been the formation of cyclic derivatives, which 
could serve as antibacterial agents with a dual inhibition system. Thus, following this design 
strategy a new series of benzoxazinediones derivatives was obtained, where a thioxo group 
replaced one or two oxo groups. The substitution of an oxo group by the thioxo group (17, 
figure 5) strongly increased anti-TB activity, although a second substitution with the thioxo 
group had only a small effect on activity (18, figure 5) (Petrlikova et al., 2010). 
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Fig. 5. General structure of 1,3-benzoxazine derivatives. 
3.4 Quinoline derivatives 
A quinoline ring is one of the moieties frequently used in new drug design. It has been 
considered a pharmacophore for the design of anti-TB agents. Diarilquinoline, denominated 
TMC207 (19, figure 6), is an adenosine ATP synthase inhibitor that is one of the most 
important quinoline derivatives with anti-TB activity. TMC207 is currently in Phase II 
clinical trials. Also, butanamide has been established as an important pharmacophore with 
good antibacterial activity and the carbohydrazone moiety is also known as a 
pharmacophore group. Based on the above, the design of new quinoline derivatives with 
active carbohydrazine and butanamide moieties in 3 and 4-position, respectively, has been 
carried out. The SAR study of these compounds shows that the presence of a trifluoromethyl 
group at 8-position increases activity; however, the introduction of a fluoro group in 6-
position partially decreases activity (20, figure 6) considering these type of compounds non-
toxic (Eswaran et al., 2009). Following the development of mefloquine analogs (21, figure 6) 
in a series of compounds (22, figure 6), good anti-TB activity has been attributed to the 
presence of pharmacologically active heterocyclic groups such as pyrazole, imidazole, and 
indole rings on the quinoline ring. Surprisingly, compounds with a hetoaromatic pyrazole 
ring have activity against resistant strains, which can be attributed to the presence of 
substituents (electron donating groups) that stabilize the pyrazole ring, making the 
quinoline ring a more active entity (Eswaran et al., 2010). 
The conformational restriction-like strategy in flexible drugs is extensively used in medicinal 
chemistry. This helped determine steric requirements of receptor-drug interaction and 
identification of new structures with high efficiency and selectivity. Based on this, Goncalves 
et al studied the conformational restriction of the piperidinyl ring of mefloquine through the 
construction of an oxazolidine ring and different substituents on the phenyl ring (23, figure 6). 
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Conformational restriction showed that the introduction of an oxazolidine core in the 
mefloquine structure enhances anti-TB activity. Although, the activity of these compounds is 
affected by substituents on the aromatic ring bound to C-17 of the oxazolidenyl nucleus. 
Compounds that show hydroxyl or methoxyl groups, which are both electron donators and 
capable of forming strong hydrogen bonds, in general are active. In contrast, with one 
exception, compounds with nitro or halogenated groups (electron withdrawing groups and 
capable of forming only weak hydrogen bonds), are inactive (Goncalves et al., 2010). Thus, 
mefloquine has been used to design anti-TB agents. Modifications in previous reports included 
introduction of a hydrazone linker into mefloquine at 4-position, substitution of a piperidine 
with a piperazine ring and extension of the basic terminus of the piperazine ring at 4-position. 
Additionally, isoxazole is emerging as one of the most powerful hits in high-throughput 
screening (HTS) against M. tuberculosis. Both types of compounds show an aromatic ring, a 
two-atom linker and a five or six member ring. Hybridization strategies have been the basis for 
the design of new chemical entities by Mao et al (24, figure 6). One problem that has been 
detected in this type of compounds is poor penetration of acid derivatives through the M. 
tuberculosis cell wall. It is suggested that these compounds may act as prodrugs when ester 
derivatives generate acid derivatives (24, figure 6). SAR studies of these compounds show that 
when a methyl group replaces a trifluoromethyl group, it is 10 times less active, suggesting 
that electronic effects may play an important role in anti-TB activity. Additionally, steric effects 
can affect anti-TB activity. Subsequently, making use of drug design strategies, the authors 
included ester bioisosteres, such as amides and oxadiazole, although none of these bioisosteres 
showed better activity than ester derivatives. It was determined that 2 and 8-trifluoromethyl 
groups on quinoline ring (24, figure 6) are essential for anti-TB activity against replicative 
bacteria (Mao et al., 2009). 
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Fig. 6. Quinoline as scaffold for designing new anti-TB agents. 
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Isoxazole derivatives have also been reported as anti-TB agents, in particular compound 25 
(figure 7) with an activity of 2.9 μM, which is comparable to INH and (RIF) (Kini et al., 
2009). Thus, quinoline and oxazole ring hybridization has been used to develop a series of 
new anti-TB agents (26, figure 7) which have good activity due to the presence of aryl 
substituents at 2-position on quinoline ring. SAR studies show that the introduction of a 1,3-
oxazole ring significantly increases activity, obtaining compounds that are more potent than 
INH (Eswaran et al., 2009). In search of a new moiety that confers anti-TB activity with low 
cytotoxicity, Yang and colleagues reported methoxybenzofuro2,3-bquinoline derivatives 
(27, figure 7), compounds that have a potent M. tuberculosis growth inhibition of 99% at low 
concentrations (0.20 µg/mL) and very low cytotoxicity against VERO cells with an Inhibitor 
concentration 50 (IC50) value of > 30.00 µg/mL (Yang et al., 2009). 
Several studies have analyzed modifications in the quinolone ring, mainly at 3, 6 and 7-
position. Wube et al proposed a new strategy for anti-TB agent development. They made a 
modification in the 2-position, including an aliphatic side chain with various degrees of 
unsaturation, lengths chains, and double bond positions (28, figure 7). Their results showed 
that increasing the chain length enhances anti-TB activity, showing optimal activity with 14 
C atoms. If there is an increase of more carbon atoms in the chain, activity decreases 
dramatically. This behavior has also been described for ciprofloxacin derivatives where 
lipophilicity could play an important role in anti-TB activity. Other research has determined 
that the saturated aliphatic chain has less activity than unsaturated analogues. This means 
that unsaturation of an aliphatic chain is an essential structure for in vitro anti-TB activity 
(Wube et al., 2010). 
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Fig. 7. Quinoline and oxazole derivatives as anti-TB agents. 
On the other hand, both phenazine and quinoxaline rings are considered bioisosteres of the 
quinoline ring. In this focus, phenazine derivatives are a class of useful compounds for new 
anti-TB agent development, particularly Tubermicyn B and Clofazimine (phenazine 
derivatives). Likewise, De Logu et al developed new agents that show activity (29, figure 8) 
in a concentration range of 0.19 to 3.12 mg/L against M. tuberculosis-resistant clinical 
isolates. Interestingly, they found that this series of compounds were ineffective in 
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inhibiting the growth of INH resistant strains. Compounds that had exocyclic groups, which 
confer different lipophilic and electronic properties, but with a size similar to INH, such as 
the phenylamide methyl lipophilic group in 4-position, were the most active. In contrast, the 
same group in 3-position reduced activity 100-fold. Also, phenazine derivatives with 
electron withdrawing groups in 2 and 3-position have values with similar biological activity. 
These results show the importance of the arylic moiety as a pharmacophore for 
phenazinecarboxamide anti-TB agents. While phenazine´s mechanism of action is still 
unknown, it is hypothesized that it could act as a cellular superoxide bismutase inhibitor. 
We know that the compound Lomofungin (1-carbomethoxy-5-formyl-4,6,8-
trihydroxyphenazine) is capable of inhibiting DNA-dependent RNA polymerase, with both 
options being possible mechanisms of action of phenazine derivatives (De Logu et al., 2009).  
Quinoxalines are compounds with a broad spectrum of biological activities. Quinoxaline-N-
oxide derivatives are known as M. tuberculosis bioreductor agents. In this type of 
compounds missing N-oxide groups have led to the loss of anti-TB activity. In this sense, 
Monge´s group developed over 500 derivatives of quinoxaline (30, figure 8), demonstrating 
the importance of this group for generating a new class of anti-TB drugs. Interestingly, this 
research group determined that the quinoxaline compounds obtained have activity on non-
replicating bacteria, which could lead to shorter anti-TB therapies (Vicente et al., 2008). 
Finally, a compound denominated ER-2 is a new analogue of quinoline derivatives (31, 
figure 8) that is a gyrase supercoiling inhibitor that has potency similar to Ciprofloxacin 
with a minimum inhibitory concentration 90 (MIC90) of 0.5 µg/mL (Sainath et al, 2009). 
 
N
N
OR
N
N
N
O
O
W
R7
R6
N
H
N
N
N
O
Cl
29
+
+
-
-
30
31  
Fig. 8. General structure of phenazine-1-carboxamides, quinoline and quinoxaline 
derivatives. 
3.5 Azoles derivatives 
One of the most important strategies for effective anti-TB agent design has been the 
development of cell wall biosynthesis inhibitors. Azole derivatives have shown interesting 
anti-TB antimicrobial activity, inhibiting the bacteria by blocking lipid biosynthesis and/or 
additional mechanisms. Thus, by hybridization of 1,2,4-triazoles and a thiazole moiety, new 
anti-TB agents were discovered (32, figure 9). These molecules with a highly electronegative 
part at the sulfhydryl groups have emerged as new anti-TB compounds. Particularly, Schiff 
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bases derivatives probably due to its ability to increase penetration into the bacterial cell 
(Shiradkar et al, 2006). 
Benzimidazole is an important pharmacophore in drug discovery. Gill et al propose 1,2,3-
triazole and benzimidazole ring hybridization as design strategies of new anti-TB agents. 
They have also considered the use of electron withdrawing groups in the benzimidazole 
ring, which are present in molecules with anti-TB activity. They obtained compound 33 
(figure 9) that could be considered a lead series. Their optimization led to determine that 
substitutions with electron withdrawing groups produce a loss of anti-TB activity (Gill et al., 
2008). A new strategy of hybridization between benzimidazole and a 1,2,4-triazole ring has 
obtained a series of compounds (34, figure 9). Using a SAR study, it was determined that 
these compounds enhance biological activity by increasing electronegativity of the molecule, 
but surprisingly when a trifluoromethyl group (high electronegativity) was introduced, it 
produced a substantial loss of activity, which could be due to a delay in intracellular 
transport (Jadhav et al., 2009). Following with the use of a benzimidazole ring as a drug 
design, Klimešova and cols replaced a nitrogen atom with a corresponding oxygen atom 
(isosteric) (35, figure 9) to obtain a series of benzylsulfanyl benzoxazole derivatives. They 
consider alkylsulfanyl derivatives of pyridine, benzimidazole and tetrazole as new anti-TB 
agents, which present anti-TB activity due to the presence of the alkylsulfanyl group bound 
to an electron deficient carbon atom in the heterocycle ring. Thus, a SAR study of these 
compounds indicates that anti-TB activity is attributed to the presence of a benzyl moiety at 
2-position on the benzoxazole ring, denoting that anti-TB activity is not affected by electron 
withdrawing or electron donating susbstituents on the benzyl moiety. It is important to note 
that the presence of two nitro groups on benzyl led to the most active compound (MIC 2 
µmol/L), which may be related to compounds such as PA-824 and OPC-67683, that also 
show nitro groups. Research postulated as a mechanism of action the generation of active 
species that act on biochemical targets. Additionally, regression coefficient values for log P 
show that anti-TB activity increases when lipophilicity decreases (Klimesova et al., 2008).  
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Fig. 9. Triazole and benzimidazole scaffold for designing new anti-TB agents. 
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Another strategy using 1,2,4-triazole and 1,3,4-thiadiazole rings, led to the development of 
new anti-TB agents (36, figure 10). Guzeldemerci et al obtained compounds that inhibit 90% 
M. tuberculosis with a concentration greater than 6.25 µg/mL. In addition, the benzothiazole 
moiety has been recognized for anti-TB design. Both benzothiazole and 1,2,4-triazole moiety 
were considered to obtain new structures based on hybridization (37, figure 10). 
Benzothiazole derivatives with 4-methoxy groups showed the best anti-TB activity; 
however, compounds obtained by hybridization with the 1,2,4-triazole-benzothiazole 
moiety with the best activity were those with an electron withdrawing substituent (Cl) on 
the benzothiazole ring (Patel et al., 2010). 
Another moiety considered in anti-TB agent design has been isopropylthiazole. Based on 
this a series of isopropylthiazole derived triazolothiadiazoles, triazolothidiazines 
derivatives, and mannich bases were developed. The SAR study of the thiadiazoles series 
(38, figure 10) shows that these compounds have excellent activity against M. tuberculosis 
when they have fluorinated (highly electronegative) substituents that increase molecule 
lipophilicity, producing hydrophobic molecule interactions with specific binding sites on 
either receptors or enzymes (Suresh Kumar et al., 2010). 
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Fig. 10. Triazole derivatives as anti-TB agents. 
One of the strategies employed in the development of new drugs is in silico screening based 
on drug structure, structural data of protein and a virtual library of compounds. With this 
strategy Izumizono et al identified 5 classes of compounds that have an affinity for the 
active site of enoyl-acyl carrier protein reductase. They determined that these compounds 
have a structural skeleton of dibenzofuran, acetoamide, triazole, furyl and methoxy phenyl 
groups (figure 11) that completely inhibit M vanbaalenii growth with no toxic effect on 
mammalian cells. Binding mode prediction determined that compounds 39, 40 and 41 form 
common hydrogen bonds with amino acid Lys 165 of the active site of the reductase protein. 
Lys 165 is an amino acid residue that is known to form hydrogen bonds with INH. This 
shows that hydrogen bond formation with Lys 165 tends to be effective in the design of new 
drugs. In drug-interaction, the triazole group of compound 39 forms hydrogen binds with 
www.intechopen.com
 
Drug Development – A Case Study Based Insight into Modern Strategies 
 
222 
the active side, and the methoxy and sulfonyl groups in compound 40 and the sulfonyl 
group in compound 41, respectively, form hydrogen bonds with Lys 165 (Izumizono et al., 
2011). 
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Fig. 11. Dibenzofurane, triazole, methylphenyl and acetamide moiety in compounds with 
anti-TB activity. 
Other derivatives of azoles are pyrazoles. Their activity has been tested against M. tuberculosis. 
SAR studies show that the presence of a para-chlorobenzoyl moiety in C4-position on the 
pyrazole ring is essential for anti-TB activity. Results of a series of pyrazole derivatives, 
generally show that cyclohexylthio substituted pyrazole derivatives are more active than 
arylthio substituted systems. An excellent activity is presented when a para-nitrophenilthio 
ring is incorporated on a pyrazole ring (42, figure 12) (Manikannan et al, 2010). 
Thiazoles are compounds that contains sulfur and nitrogen atom in its structure, and have 
been the basis of clinically used compounds. Therefore Samadhiya and colleagues consider 
it a basis of anti-TB agent design. In one study, which synthesized a series of new thiazoles 
(43, figure 12), it was demonstrated through SAR analysis that compounds with nitro 
groups show greater biological activity on M. tuberculosis than compounds with Cl and Br 
atoms, although these derivatives (Cl and Br) have better activity than other compounds. 
Finally, they found that the activity of the compound depends on the nature of the 
substituent groups (electron withdrawing) with the following sequence NO2 > Cl > Br > 
OCH3 < OH > CH3 (Samdhiya et al., 2010). 
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Fig. 12. General structure of pyrazoles and thiazoles derivatives as anti-TB agents. 
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On the other hand, hybridization of Spiro compound and pyrrolo2,1-b thiazole, an 
unusual ring with different biological properties, particularly permitted the obtention of 
pyrrolothiazoles derivatives (44, figure 13) that present a MIC of 0.007 µM against M. 
tuberculosis, being more potent than INH and Ciprofloxacin (Karthikeyan et al., 2010) . 
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Fig. 13. Spiro-pyrrolothiazoles derivative with anti-TB activity. 
3.6 Hydrazides/hydrazones derivatives 
Hydrazide/hydrazone is a class of compounds that have been considered for new anti-TB 
drug design. An example is diflunisal, a hydrazide/hydrazone derivative, which has dual 
effect acting with antimicrobial/anti-inflammatory properties. Furthermore, in 
thiazolylhydrazone derivatives, SAR studies have found that substitutions on the phenyl 
ring affect anti-TB activity (45, figure 14) (Turan-Zitouni et al., 2008). Another example of a 
thiazolylhydrazine is compound 46 (figure 14), which has high anti-TB activity with a IC50 
of 6.22 µg/mL and low toxicity (CC50> 40 µg/mL). Here, a pyridyl moiety plays a direct 
role related to anti-TB activity (Turan-Zitouni et al, 2010). Pyridine is a moiety known in the 
design of anti-TB agents. Considering this, and using hybridization technique, Sankar et al 
developed a series of compounds with potential anti-TB activity (47, figure 14), although in 
many cases as this, the use of this technique did not produce any agent with excellent 
activity against M. tuberculosis (Sankar et al, 2010). 
New designs have been made by molecular hybridization of E-cinamic acid and 
guanylhydrazones. Based on an empirical analysis of SAR, Bairwa and colleagues 
determined that electronic and steric parameters have an important role in the activity of 
these compounds on M. tuberculosis (48, figure 14).They remain the basis of new anti-TB 
agents (Bairwa et al, 2010). 
3.7 Nitrogen heterocyclic derivatives 
Purines are an important group in the design of anti-TB agents. In these compounds (49, 
figure 15), activity depends on the substituents present in C2, C6 and N9 of the purine ring 
(Correia et al., 2009). In 6,9-disubtituted purine derivatives, activity increases substantially 
when a Cl atom is introduced in the 2-position. Interestingly, purine derivatives with thienyl 
substituents exhibit better activity in non-replicating bacteria, although in these compounds 
a Cl atom in 2-position is not beneficial for activity. Additionally, it has been determined 
that purine N-9 is important for activity, in the case of purine C-8, an atom can be 
exchanged without losing activity and a change in purine N-7 results in a loss of activity, 
although there are 7-deazapurines derivatives (50, figure 15) that could be compared with 
RIF (Khoje et al., 2010).  
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Fig. 14. Hydrazone derivatives as anti-TB agents. 
 
N
N
N
N
R1
R2
N
R R´
N
N
Y
X
B
A
O
R
z
49 50  
Fig. 15. Purine derivatives as anti-TB agents. 
Heterocycles with one nitrogen atom, especially pyrimidines have potential therapeutic 
applications as anti-TB agents, but there are few reports. For this reason, the design of new 
pyrimidine derivatives is a viable option (51, figure 16). However, neither compound has an 
activity comparable to reference drugs, although it has been described that the substituent 
nature in 2-position can modulate cytotoxic activity (Singh et al, 2011). 
On the other hand, thymidine monophosphate kinase of M. tuberculosis (TMPKmt) is a 
prominent target for the development of anti-TB drugs. TMPK is the last specific enzyme for 
dTTP synthesis and is a key enzyme in M. tuberculosis metabolism. This enzyme is different 
from human enzyme analogs (22% homology). TMPK inhibitors have been developed with 
single or multiple chemical modifications of the pyrimidine moiety and thymidylate sugar. 
In particular benzyl-thymine derivatives have been remarkable TMPK inhibitors, which has 
led to the proposal of new modifications such as: chain length in para-position on the benzyl 
ring, saturation of the alkyl chain, functionalization of the chain group and substitution at 5-
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position of the core base. This has led to more selective compounds on TMKP that 
correspond to benzyl-pyrimidines substituted by a chain length of 4 carbons and a terminal 
carboxylic acid function. Docking of molecule 52 (figure 16) on TMPKmt showed that the 
hydrogen of the thymine and acid group can interact with Arg95 (Gasse et al., 2008). 
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Fig. 16. General structure of pyrimidine derivatives as anti-TB agents. 
Pyridine derivatives have also been described as anti-TB agents, an example is compound 53 
(figure 17), which presents inhibitory activity with an IC50 value of 0.38 µM, suggesting that 
its possible mechanism of action is through glutamine synthetase inhibition. This would be 
the first inhibitor compound not derived from amino acids (Odell et al, 2009). Another series 
of pyridine derivatives were developed by Fassihi et al who synthesized compound 54 
(figure 17), a potent anti-TB agent with activity similar to RIF. The results of these 
compounds showed that an imidazole group as a substituent is equivalent to a nitro phenyl 
group, which has been reported in anti-TB agents derived from 1,4-
dihydropyridinecarboxamides (Fassihi et al., 2009). 
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Fig. 17. Pyridine derivatives with potential activityanti-TB. 
Another important heterocyclic for the design of anti-TB agents is the pyridazine moiety. In 
these compounds a relationship between Br, Cl and CH3 substituents, respectively, with Br 
and vinyl has been found with a favorable anti-TB activity. In these compounds there is an 
influence of the substituents X in para-position on the aromatic ring, where the activity is 
increased in the following order: CH3 < Cl < Br with the activity being affected by the R1 
substituents, where the most active compounds have a CH3 group (55, figure 18) (Mantu et 
al., 2010). 
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Fig. 18. N-substituted-pyridazinones derivatives. 
3.8 Other derivatives 
Several studies indicate that thiosemicarbazone derivatives can be used in TB therapy and 
prophylaxis. Previous studies of 1H-2-thiosemicarbazoneindolinone derivatives indicate 
that halogenation of R1, elongation of the alkyl chain in R2, substitutions of the alkyl chain 
in R2 with cyclohexyl or phenyl, and the presence of a substituent in R3, are more efficient 
for increasing anti-TB activity, while R1 substitutions with a nitro group produce the most 
active compounds. The presence of a morpholine ring in Schiff bases substituted in R1 with 
a nitro group also has a significant impact on anti-TB activity. The results of biological 
activity of this new series indicate that the elongation of the alkyl chain increases activity. 
This enhanced activity is related to lipophilicity properties and confirmed by values of Log 
P compounds. Also, replacement of the alkyl chain in R2 and phenyl unsubstituted 
ciclohexyl has led to more active compounds (56, figure 19). The absence of substitutions at 
N1 on the indole ring and increased lipophilicity appear to be responsible for high activity 
against M. tuberculosis (Guzel et al., 2008). An example of thiosemicarbazone-derived 
compounds that have exhibited important anti-TB activity with an IC50 value of 2.59 
uM/mL, is compound 57 (figure 19) (Karali et al., 2007). 
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Fig. 19. General structure of 1H-indole-2,3-dione 3-thiosemicarbazone with anti-TB activity. 
Other moieties used in the design of anti-TB agents are phenazine and benzothidiazine. In 
particular, benzothidiazine 1,1-dioxide constituents are an important class of anti-TB agents 
(58, figure 20). A SAR study of this series of compounds indicates that the furan/thiophene 
group linked to benzothidiazine through a methylen bridge exhibits good activity against 
TB. It is important to point out that a conjugated thiophene derivative shows moderate 
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activity and is enhanced when it presents a nitrofuran group. However, elimination of the 
methylene group with a carbonyl group leads to a dramatic loss of activity. Finally, Kamal 
et al postulated piperazine-benzothidiazine with methylene linkage (59, figure 20) as an 
attractive moiety for the design of anti-TB agents (Kamal et al., 2010). 
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Fig. 20. Benzothiadiazine derivatives as anti-TB agents. 
The creation of a hybrid compound has been a frequent strategy for the design of anti-TB 
agents. One example is compound 60 (figure 21), formed from dibenzofuran and 2,2-
dimethylpyran subunits. SAR studies and modifications of benzofurobenzopyran have 
demonstrated less active compounds such as compound 61, where the furan B ring is replaced 
by an ether linker, a single carbon-carbon bond, a carbonyl group, a hydroxymethylene or a 
methylene group. Even modifications such as acylation and bromination in 5-position on the C 
ring have produced inactive compounds, thus, it has been suggested as a basis for the 
pharmacophore structure of compound 60. In this sense, Termenzi et al has carried out the 
synthesis of more derivatives of compound 60, finding that substitutions with a hydroxy, 
methoxy, or halogen group on benzofurobenzopyran increases anti-TB activity. Although, 
hydroxy compounds with good activity showed, unfortunately, cytotoxic activity on VERO 
cells. Halogenated compounds with a Cl or Br atom in 8, 9 and 11-position, exhibit increased 
potency compared with compound 60. SAR analysis shows that electronic effects of 
substituents on the A ring play a dramatic role in anti-TB activity. In addition, potency was 
significantly decreased when the A ring was substituted by an electron withdrawing group. In 
contrast, electron donating group substitutions such as hydroxy or methoxy show a significant 
increase in activity (62, figure 21). While all compounds showed a possible mechanism of 
action of interaction with lipid biosynthesis of the M. tuberculosis cell wall, a specific compound 
was an epoxy-mycolate synthesis inhibitor (Termentzi et al., 2010). 
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Fig. 21. Structure of benzofurobenzopyrane as anti-TB agents. 
Other compounds containing a phthalimide moiety have been described as biophoro to 
design new prototypes of drug candidates with different biological activities. It has been 
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shown that hybridization of both phthalimide (Thalidomide) and sulfonamide (Dapsone) 
moiety leads to compounds with activity against M. leprae. In this sense, the design of new 
products such as anti-TB agents is interesting. SAR study of a series of derivatives showed 
that if the pyrimidine ring is substituted in any position or changed by an isosteric, this 
decreases activity on M. tuberculosis. Amino group substitutions by another phthalimide 
ring also lead to a decrease in anti-TB activity (63, figure 22). Modifications in the pyridine 
ring decrease anti-TB activity. Introduction of a phthalimide group by molecular 
hybridization did not produce compounds with an activity similar to INH; however, it 
allows for compounds with MIC values similar to PZA (Santos et al., 2009). 
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Fig. 22. Phthalimide derivatives as anti-TB agent.  
Among families of compounds that act as inhibitors of the FAS-II system we can mention 
diphenyl ether systems that interact with enzyme-cofactor binary complex, but, recently 
new compounds such as indols, benzofuran and cinnamic acid derivatives have been 
reported. Development of new cinnamic acid derivatives would focus on more specific 
FAS-II inhibitors. From a series of compounds developed (figure 23) it was determined 
that addition of an alkyl chain increases anti-TB activity. The best results are associated 
with an acceptable lipophilicity parameter that appears when a geranyl chain is 
incorporated. This led to compound 64, the most active substance with an MIC of 0.1 
µg/mL (Yoya et al., 2009). 
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Fig. 23. Cinnamic derivatives. 
It has also been shown that amide derivatives of fatty acids have anti-TB activity. Due to their 
nature these compounds are designed to penetrate bacterial cells, which can be useful for 
studying the mechanism of INH resistance as this can also be due to factors such as mutations 
in unknown genes, decreased permeability, or increased efflux (D´Oca et al., 2010). 
64 
63 
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4. Drugs in clinical trials 
In drug design, bicyclic nitroimidazofurane derivatives that have anti-TB activity, such as 
CGI-17341 (65, figure 24) have been developed; however, this compound is mutagenic. 
This has led to the development of PA-824 (66, figure 24), which is currently in phase II 
clinical studies and has a long half-life. Its mechanism of action is to inhibit M. tuberculosis 
cell wall lipids and protein synthesis; however, it also inhibits non-replicating bacteria. 
Additionally, it was reported that PA-824 is a prodrug that is metabolized by M. 
tuberculosis before exercising its effect and may involve bioreduction of aromatic nitro 
groups to generate a radical intermediate nitro. 
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Fig. 24. Anti-TB compounds in clinical trials. 
www.intechopen.com
 
Drug Development – A Case Study Based Insight into Modern Strategies 
 
230 
The interest in derived oxazoles as anti-TB compounds led to the development of OPC-
67683 (67, figure 24), which has excellent activity in vitro in sensitive and resistant M. 
tuberculosis strains. It has a long half-life and its mechanism of action involves inhibition of 
the synthesis of keto-mycolic, and methoxy-mycolic acid, although is possible another 
possible mechanism of action or interaction with another drug target in M. tuberculosis. 
OPC-67683 also acts as a prodrug, since M. tuberculosis metabolizes it and produces as a 
product desnitro-imidazooxazole metabolite. 
TMC207 (68, figure 25) is a quinoline derivative with potent anti-TB activity in susceptible, 
DR and XDR strains. It is well absorbed in humans with a long half-life and is currently in 
phase II clinical studies. Its mechanism of action involves inhibition of ATP synthase that 
binds the M. tuberculosis membrane and there is a synergistic effect between TMC207 and 
PZA. Other compounds with very promising anti-TB activity are LL-3858 and OPC-37306 
(69 and 70, figure 25) (Rivers et al., 2008). Some other examples of anti-TB compounds in 
clinical trials are showed in table 1 (Janin, 2007; Palomino et al., 2009; Shi & Sugawara, 2010) 
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Fig. 25. Anti TB compounds in clinical trials. 
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Compound Funding Target Mechanism of 
action 
Resistance 
mechanisms 
Clinical 
trial 
phase 
a) Nitroimidazoxacines    
PA-824 GATB F420 dependent 
nitroreductase 
Inhibition of 
proteins and cell 
wall biosynthesis 
Rv0407, Rv3547, 
Rv3261 and 
Rv3262 
mutations 
II 
OPC-67683 Otsuka Nitroreductase Inhibition of 
mycolic acid and 
cell wall 
biosynthesis  
Rv3547 
mutations 
II 
b) Fluoroquinolones    
Moxifloxacin Bayer, 
CDC, 
NIH, FDA 
DNA girase Inhibition of DNA 
biosynthesis 
gyrA mutations III 
Gatifloxacine NIH DNA girase Inhibition of DNA 
biosynthesis 
gyrA mutations III 
c) Diarilquinolines    
TMC207 Tibotec F1F0 ATP 
sintetase 
 
Inhibition of ATP 
synthesis and 
disruption of 
membrane 
potential 
atpE mutations II 
d) Oxazolidinones    
Linezolid NIH, 
Pfizer 
Ribosome Inhibition of 
protein 
biosynthesis 
rRNA 23S 
mutations 
Pre-trial 
e) Dietilamins    
SQ109 Sequella Un known Inhibition of cell 
wall biosynthesis 
Unknown I/II 
f) Pirrols    
LL3858 Lupin Unknown Unknown Unknown  I 
Table 1. Some compounds under clinical trials 
5. Conclusion 
Tuberculosis remains the leading infectious disease worldwide, despite the availability of 
TB chemotherapy and the BCG vaccine. This is further demonstrated by the fact that half a 
year of treatment with multiple drugs is needed. Recent genetic and genomic tools as well as 
high-throughput screening, and structure-based drug design strategies have allowed the 
discovery of new anti-TB drugs. These are increasingly receiving more attention, and a large 
number of new compounds or derivatives from existing drugs are under investigation. With 
this and a better understanding of the unique biology of TB, more targets will be validated, 
and hopefully a pattern will emerge that will help us reach the goals of more potent 
compounds that allow multiple stages and drug targets to be addressed. 
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